I-Mab Reports Q1 2025 Financial Results
Ticker: NBP · Form: 6-K · Filed: May 15, 2025 · CIK: 1778016
Sentiment: neutral
Topics: financial-results, 6-K, quarterly-report
TL;DR
I-Mab dropped Q1 2025 earnings on 5/15. Check financials.
AI Summary
I-Mab announced its unaudited financial results for the three months ended March 31, 2025, on May 15, 2025. The company, headquartered in Rockville, MD, is a foreign private issuer filing a Form 6-K report. This filing provides an update on their financial performance for the first quarter of 2025.
Why It Matters
This filing provides investors with the latest financial performance data for I-Mab, crucial for assessing the company's current health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial results filing and does not contain new material events or significant changes.
Key Players & Entities
- I-Mab (company) — Registrant
- May 15, 2025 (date) — Announcement date
- March 31, 2025 (date) — Reporting period end date
- Rockville, MD (location) — Company headquarters
FAQ
What type of filing is this Form 6-K?
This Form 6-K is a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
When did I-Mab announce its Q1 2025 financial results?
I-Mab announced its financial results for the three months ended March 31, 2025, on May 15, 2025.
What is the principal executive office address for I-Mab?
The principal executive offices of I-Mab are located at 2440 Research Boulevard, Suite 400, Rockville, MD 20850.
Does I-Mab file annual reports under Form 20-F or Form 40-F?
I-Mab indicates that it files annual reports under cover of Form 20-F.
What is the SIC code for I-Mab?
The Standard Industrial Classification (SIC) code for I-Mab is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 15, 2025 regarding I-Mab (NBP).